As of Sep 26, 2026, Haemonetics Corporation had total assets of $2.4 billion. Total assets were down 1.3% from a year earlier. Stockholders' equity was $898.5 million. It held $260.7 million in cash and investments against $1.1 billion of total debt, net debt of $875.9 million. The current ratio, current assets divided by current liabilities, was 2.84.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2027
Sep 26, 2026
|
FY 2026
Mar 28, 2026
|
FY 2025
Mar 29, 2025
|
FY 2024
Mar 30, 2024
|
FY 2023
Apr 1, 2023
|
FY 2022
Apr 2, 2022
|
FY 2021
Apr 3, 2021
|
FY 2020
Mar 28, 2020
|
FY 2019
Mar 30, 2019
|
FY 2018
Mar 31, 2018
|
FY 2017
Apr 1, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash |
261
-12.0%
|
245
-20.0%
|
307
+71.6%
|
179
-37.1%
|
284
+9.6%
|
259
+34.9%
|
192
+40.1%
|
137
-18.9%
|
169
-6.0%
|
180
+29.1%
|
140
+21.2%
|
| Cash and investments |
261
-12.0%
|
245
-20.0%
|
307
+71.6%
|
179
-37.1%
|
284
+9.6%
|
259
+34.9%
|
192
+40.1%
|
137
-18.9%
|
169
-6.0%
|
180
+29.1%
|
140
+21.2%
|
| Receivables |
225
+8.6%
|
217
+7.0%
|
203
-1.9%
|
207
+15.3%
|
179
+12.4%
|
159
+24.9%
|
128
-22.8%
|
165
-10.7%
|
185
+22.4%
|
151
-1.0%
|
153
-2.8%
|
| Inventory |
305
-9.3%
|
306
-16.1%
|
365
+15.1%
|
317
+22.3%
|
259
-11.5%
|
293
-9.2%
|
323
+19.4%
|
270
+39.1%
|
194
+20.9%
|
161
-9.1%
|
177
-5.4%
|
| Total current assets |
856
-4.9%
|
835
-10.7%
|
935
+21.6%
|
769
-0.1%
|
770
+1.8%
|
756
+9.0%
|
694
+14.9%
|
604
+4.8%
|
576
+10.5%
|
521
+2.2%
|
510
+4.5%
|
| Property and equipment, net |
308
+5.3%
|
306
+7.6%
|
284
-8.8%
|
311
+0.2%
|
311
+20.3%
|
258
+18.8%
|
218
-14.1%
|
253
-26.3%
|
344
+3.6%
|
332
+2.6%
|
324
-4.1%
|
| Goodwill |
657
+8.4%
|
656
+8.6%
|
604
+6.9%
|
565
+21.2%
|
466
-0.2%
|
467
+0.2%
|
466
+121.4%
|
211
-0.1%
|
211
-0.3%
|
211
+0.3%
|
211
-21.3%
|
| Total assets |
2,411
-1.3%
|
2,396
-2.2%
|
2,451
+11.6%
|
2,196
+13.5%
|
1,935
+4.0%
|
1,860
+2.2%
|
1,820
+43.6%
|
1,267
-0.6%
|
1,275
+3.0%
|
1,237
-0.1%
|
1,239
-6.1%
|
| Liabilities and equity | |||||||||||
| Accounts payable |
72
+16.1%
|
51
-23.8%
|
67
-8.7%
|
73
+14.7%
|
64
+9.5%
|
58
+16.1%
|
50
-0.9%
|
51
-19.9%
|
63
+14.6%
|
55
+28.6%
|
43
+8.3%
|
| Total current liabilities |
301
-45.1%
|
283
-51.1%
|
578
+92.5%
|
300
+19.3%
|
252
-43.1%
|
442
+74.5%
|
253
-7.8%
|
275
+16.6%
|
236
-38.7%
|
385
+82.2%
|
211
+13.8%
|
| Stockholders' equity |
898
+5.8%
|
796
-3.0%
|
821
-14.5%
|
960
+17.4%
|
818
+9.2%
|
749
+2.4%
|
732
+24.6%
|
587
-12.1%
|
668
-11.2%
|
752
+1.7%
|
740
+2.5%
|
| Debt | |||||||||||
| Debt due within a year |
23
-92.6%
|
20
-93.8%
|
325
+3076.2%
|
10
-13.2%
|
12
-94.5%
|
214
+1158.5%
|
17
-77.9%
|
77
+178.2%
|
28
-85.8%
|
194
+212.4%
|
62
+41.5%
|
| Long-term debt |
1,114
+21.0%
|
1,220
+32.4%
|
921
+15.5%
|
798
+5.8%
|
754
+34.8%
|
559
-19.0%
|
691
+126.0%
|
306
-5.3%
|
322
+442.6%
|
59
-76.6%
|
254
-30.4%
|
| Lease liabilities |
—
|
50
-14.4%
|
59
-11.4%
|
66
+4.8%
|
63
+0.3%
|
63
-11.0%
|
71
+19.1%
|
59
|
—
|
—
|
—
|
| Total debt |
1,137
-7.2%
|
1,290
-1.1%
|
1,305
+49.3%
|
874
+5.4%
|
829
-0.9%
|
836
+7.5%
|
778
+76.2%
|
442
+26.2%
|
350
+38.0%
|
254
-19.7%
|
316
-22.7%
|
| Net cash |
-876
+5.6%
|
-1,045
-4.7%
|
-998
-43.6%
|
-695
-27.7%
|
-544
+5.6%
|
-577
+1.5%
|
-586
-92.4%
|
-305
-68.4%
|
-181
-145.9%
|
-74
+58.3%
|
-176
+39.9%
|
| Ratios | |||||||||||
| Current ratio |
2.84x
|
2.95x
|
1.62x
|
2.56x
|
3.06x
|
1.71x
|
2.74x
|
2.20x
|
2.44x
|
1.35x
|
2.42x
|
| Debt to equity |
1.27x
|
1.62x
|
1.59x
|
0.91x
|
1.01x
|
1.12x
|
1.06x
|
0.75x
|
0.52x
|
0.34x
|
0.43x
|
| Debt to EBITDA |
3.97x
|
4.81x
|
3.87x
|
3.33x
|
3.32x
|
4.69x
|
4.47x
|
2.07x
|
1.81x
|
1.74x
|
4.49x
|
| Return on equity |
11.56%
|
12.22%
|
20.43%
|
12.25%
|
14.11%
|
5.79%
|
10.86%
|
13.03%
|
8.24%
|
6.06%
|
-3.55%
|
| Return on assets |
4.31%
|
4.06%
|
6.84%
|
5.35%
|
5.96%
|
2.33%
|
4.37%
|
6.04%
|
4.32%
|
3.68%
|
-2.12%
|
| Book value per share |
19.74
|
17.60
|
17.02
|
18.90
|
16.21
|
14.66
|
14.38
|
11.67
|
13.09
|
14.37
|
14.15
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- HAE (NYSE)
- Fiscal year ends
- April 3
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 313143
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.